Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Pepcid (famotidine) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – March 2010 and June 2011

 

June 2011

Summary View

 

PRECAUTIONS

  • Prolonged QT interval has been reported very rarely in patients with impaired renal function whose dose/dosing interval of famotidine may not have been adjusted appropriately

 

ADVERSE REACTIONS

Cardiovascular:
  • Prolonged QT interval, in patients with impaired renal function, has been reported very rarely

 

March 2010

Summary View

 

ADVERSE REACTIONS

Gastrointestinal
  • hepatitis

 

-
-